Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Genprex Inc (0A8I)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.28 0.00    0.00%
30/04 - Real-time Data. Currency in USD ( Disclaimer )
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 2.28 - 2.28
Type:  Equity
Market:  United Kingdom
ISIN:  US3724462037 
SEDOL:  BS7ZNB5
Genprex 2.28 0.00 0.00%

Genprex Company Profile

 
Read the Genprex Inc company profile to learn more about the business and the management team. View Genprex Inc facts about employee data, company products and services, and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

26

Equity Type

DRC

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company’s lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes. Its product pipeline comprises Acclaim-1, which is in phase 2a clinical trial for the treatment of non-small cell lung cancer; Acclaim-2, which is in phase phase 1/2 clinical trial for the treatment of non-small cell lung cancer; and Acclaim-3, which is in phase 1/2 clinical trial for the treatment of small cell lung cancer. The company also develops ONC-001, REQORSA as a monotherapy, which is in phase 1 clinical trial to treat advance non-small cell lung cancer; and ONC-002, REQORSA with Tarceva, which is in phase 2 clinical trial to treat non-small cell lung cancer. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Contact Information

Address 3300 Bee Cave Road Suite 650-227
Austin, 78746
United States
Phone 877-774-4679
Fax -

Top Executives

Name Age Since Title
Jack A. Roth - - Chairman of Scientific & Medical Advisory Board
Brent M. Longnecker 68 2020 Independent Director
Shu Kam Mok 64 - Member of Scientific & Medical Advisory Board
Pasi Antero Janne - - Member of Scientific & Medical Advisory Board
George K. Gittes - 2020 Member of Scientific Advisory Board
George Simon - - Member of Scientific & Medical Advisory Board
James E. Rothman 73 2012 Strategic Advisor to the Board of Directors
John Rodney Varner 67 2012 Co-Founder, Chairman, President & CEO
Jose Antonio Moreno Toscano 51 2020 Independent Director
George E. Peoples - 2021 Member of Clinical Advisory Board
Michael Morse - 2021 Member of Clinical Advisory Board
William R. Wilson 74 2020 Independent Director
Andrew B. Becker - 2021 Member of Clinical Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

GNPX Price Commentary

Write your thoughts about Genprex Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Robert Owens
Robert Owens Aug 18, 2020 10:07
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy
Peter Bandurins
Peter Bandurins Mar 18, 2020 18:31
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy until 6th of April. Sell then at 6$ or 7$ mark. Drop till 3$ again and buy with a 50% discount :)
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email